|Videos|July 10, 2023
Ruxolitinib for the Management of PV
Abdulraheem Yacoub, MD, reviews data from the RESPONSE and RESPONSE-2 trials on the use of ruxolitinib for the treatment of polycythemia vera.
Advertisement
Episodes in this series
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The IMpactMF trial is being discontinued after an IDMC advised that imetelstat was unlikely to improve OS in relapsed/refractory myelofibrosis.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5